TP53 and cancer: Analyzing data from the cancer genome atlas (TCGA) and Mark Redston et al.’s study [23], we found that in different risk-stratified patients with NDBE, BE indefinite for dysplasia (BE-IND) and BE-HGD, the P53 mutation rate was positively correlated with risk stratification (Figure 1A).